Oct 12 (Reuters) - Allergan Plc
* Allergan announces settlement on Restasis® (cyclosporine ophthalmic emulsion) 0.05% patent litigation with Innopharma, Inc.
* Allergan Plc - additional details regarding settlement were not disclosed
* Allergan Plc - as a result of settlement, all Innopharma Hatch-Waxman litigation regarding Restasis patents will be dismissed
* Allergan - will grant Innopharma licenses to market generic version of Restasis in U.S. beginning Feb 24, 2024, or earlier under certain circumstances
* Allergan - under certain circumstances, co will supply, authorize Innopharma to launch an authorized generic version of Restasis on August 28, 2024 Source text for Eikon: Further company coverage: